Acadia Healthcare (NASDAQ:ACHC) Stock Price Target Raised at Guggenheim

Acadia Healthcare (NASDAQ:ACHC) had its target price increased by equities researchers at Guggenheim from $39.00 to $41.00 in a note issued to investors on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Guggenheim‘s price objective suggests a potential upside of 12.63% from the stock’s current price.

ACHC has been the topic of a number of other research reports. TD Cowen upped their price objective on Acadia Healthcare from $30.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, July 14th. Royal Bank Of Canada reiterated an “outperform” rating on shares of Acadia Healthcare in a report on Friday. KeyCorp boosted their target price on Acadia Healthcare from $30.00 to $40.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 14th. Barclays upped their price target on Acadia Healthcare from $32.00 to $35.00 and gave the stock an “equal weight” rating in a report on Thursday. Finally, Cantor Fitzgerald upped their price target on Acadia Healthcare from $30.00 to $39.00 and gave the stock a “neutral” rating in a report on Friday. Eight analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $31.77.

Acadia Healthcare Stock Up 4.6%

ACHC traded up $1.61 during trading hours on Friday, hitting $36.40. 715,103 shares of the company’s stock were exchanged, compared to its average volume of 2,827,945. Acadia Healthcare has a 12-month low of $11.43 and a 12-month high of $39.38. The firm has a 50 day moving average of $29.27 and a 200 day moving average of $26.03. The firm has a market cap of $3.39 billion, a P/E ratio of -2.89, a price-to-earnings-growth ratio of 10.39 and a beta of 0.64. The company has a current ratio of 1.57, a quick ratio of 1.57 and a debt-to-equity ratio of 1.20.

Acadia Healthcare (NASDAQ:ACHC) last released its earnings results on Wednesday, November 4th. The company reported $0.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. Acadia Healthcare had a negative net margin of 33.07% and a positive return on equity of 6.58%. The company had revenue of $895.31 million for the quarter, compared to analyst estimates of $877.76 million. During the same period in the prior year, the business earned $0.72 EPS. The firm’s quarterly revenue was up 5.1% on a year-over-year basis. Analysts predict that Acadia Healthcare will post 1.55 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ACHC. BlackRock Inc. purchased a new stake in shares of Acadia Healthcare in the 2nd quarter valued at approximately $441,685,000. Jefferies Financial Group Inc. purchased a new stake in shares of Acadia Healthcare during the 2nd quarter worth $106,458,000. Deutsche Bank AG purchased a new stake in shares of Acadia Healthcare during the 2nd quarter worth $49,746,000. First Trust Advisors LP grew its stake in shares of Acadia Healthcare by 73.0% during the first quarter. First Trust Advisors LP now owns 1,689,442 shares of the company’s stock worth $39,516,000 after purchasing an additional 712,852 shares in the last quarter. Finally, Braidwell LP grew its stake in shares of Acadia Healthcare by 76.7% during the second quarter. Braidwell LP now owns 1,141,477 shares of the company’s stock worth $33,708,000 after purchasing an additional 495,577 shares in the last quarter.

Key Stories Impacting Acadia Healthcare

Here are the key news stories impacting Acadia Healthcare this week:

• Positive Sentiment: Acadia reported Q3 revenue of $895.3 million, up 5.1% year over year and ahead of estimates, while EPS of $0.60 beat the $0.46 consensus. The company also raised its 2026 financial guidance, a key positive signal for expected performance. Acadia Healthcare Q3 results and guidance
• Positive Sentiment: RBC raised its price target to $41 from $31 and maintained an Outperform rating, signaling increased confidence in the shares. RBC price target update
• Neutral Sentiment: Cantor Fitzgerald lifted its target to $39 but kept a Neutral rating; Barclays raised its target to $35 while maintaining Equal Weight. The higher targets are supportive, but both firms stopped short of a bullish rating. Cantor Fitzgerald rating Barclays rating
• Negative Sentiment: Despite the earnings beat, EPS declined from $0.72 a year earlier to $0.60, tempering the positive results. Q3 earnings comparison

Acadia Healthcare Company Profile

Acadia Healthcare Company, Inc is a provider of behavioral healthcare services headquartered in Franklin, Tennessee. The company operates psychiatric hospitals, specialty treatment facilities and outpatient programs focused on mental health and substance use disorders.

Acadia’s services include inpatient and outpatient psychiatric care, addiction treatment, residential treatment, eating-disorder programs, and services for children and adolescents. Its facilities serve patients with a range of behavioral health conditions, including depression, anxiety, trauma-related disorders and substance use disorders.

Founded in 2005, Acadia operates primarily in the United States and also has a significant presence in the United Kingdom through its ownership of Priory, a behavioral healthcare provider.